Linked Life Data

6209474

Source:http://linkedlifedata.com/resource/pubmed/id/6209474

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1984-12-28
pubmed:abstractText
Acebutolol, a cardioselective beta-adrenergic blocking agent, was administered for 48 weeks to 11 patients with chronic stable angina in a single-blind trial for determining efficacy and safety. As expected, beta-adrenergic blockade reduced angina frequency and improved exercise performance (p less than 0.001). Three patients developed an antinuclear antibody (ANA) titer, and in two patients a low titer present during placebo treatment increased fourfold. Two patients had joint symptoms probably related to acebutolol administration. Readministration of acebutolol after the ANA returned to negative resulted in a significant rise in ANA titer in two patients tested. The other nine patients tolerated long-term acebutolol therapy without significant side effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0160-2446
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
735-8
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:articleTitle
Adverse effects of acebutolol in chronic stable angina: drug-induced positive antinuclear antibody.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't